While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in cystic fibrosis, cancer and possibly chronic pain.

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis ...

See below for Important Safety Information, including a Boxed Warning. "ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to ...

ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to-head ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...

RCT-2100 is under development for the treatment of cystic fibrosis (CF). The therapeutic candidate is an mRNA, encoding cystic fibrosis transmembrane conductance regulator (CFTR). It is administered ...

The US Food and Drug Administration has approved Alyftrek, a once-daily oral combination of vanzacaftor, tezacaftor, and ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.